Activa Deep Brain Stimulation Therapy System, Percept PC BrainSense
Medtronic, Inc. · Decision date Oct 6, 2026
What did the FDA approve?
The FDA database lists decision P960009/S542 as an approval dated 2026-10-06 for Medtronic, Inc., under product code MHY, the implanted electrical stimulator category for parkinsonian tremor. The stated change is a new stand-alone torque wrench kit configuration, Model B31020-T. It is recorded as a Real-Time Process supplement with the reason Change Design/Components/Specifications/Material.
The S542 suffix places this within the P960009 PMA, so the decision covers a supplement to that existing approval rather than a new approval of the Activa Deep Brain Stimulation Therapy System or Percept PC BrainSense system named in the title. The record does not describe the kit's materials, dimensions, intended procedural role, or supporting data, and the reported purpose is not independent evidence of safety or clinical effectiveness.
The title also links the supplement to specific system models, but whether the wrench kit applies to both is not established here.
FDA approval order statement
a new stand-alone torque wrench kit configuration (Model B31020-T)
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Neurology
- Decision date
- Oct 6, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P960009/S542
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic, Inc.
- Product code
- MHY
- Decision code
- APPR
- Decision date
- Oct 6, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, electrical, implanted, for parkinsonian tremor.
- Applicant
- Medtronic, Inc.
- Product code
- MHY
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P960009. Subsequent supplements may change the device or its indications.
FDA decision timeline
P960009 · Original PMA
MEDTRONIC ACTIVA TREMOR CONTROL SYSTEM
P960009/S542 received
Application receipt date recorded by FDA.
P960009/S546 · Related supplement
MEDTRONIC ACTIVA TREMOR CONTROL SYSTEM
P960009/S542 · FDA decision
Real-Time Process
P960009/S547 · Related supplement
Activa Deep Brain Stimulation Therapy System, Percept PC BrainSense (DBS Neurostimulator Implantable B35200)
P960009/S548 · Related supplement
Activa Deep Brain Stimulation Therapy System, Percept PC BrainSense
P960009/S545 · Related supplement
Activa Deep Brain Stimulation Therapy System, Percept PC BrainSense (B32000)
Timeline entries are records held by MedtechLedger for P960009. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P960009
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA approval | Jul 31, 1997 | FDA | |
MEDTRONIC ACTIVA TREMOR CONTROL SYSTEMP960009/S546 | Medtronic, Inc. | PMA supplement | Sep 24, 2026 | FDA |
| Medtronic, Inc. | PMA supplement | Oct 29, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 30, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Nov 8, 2026 | FDA |
Explore the linked device profile
Other records with product code MHY
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA | |
Deep Brain Stimulation (DBS) EPGP140009/S141 | ABBOTT MEDICAL | PMA supplement | Oct 28, 2026 | FDA |
| ABBOTT MEDICAL | PMA supplement | Oct 27, 2026 | FDA | |
Infinity DBS IPGP140009/S139 | ABBOTT MEDICAL | PMA supplement | Sep 23, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 7000 Central Ave., NE, Minneapolis, MN, 55432
Sources and methodology
- Original FDA record: P960009/S542
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
